| Literature DB >> 30772921 |
Latania K Logan1,2,3, Rachel L Medernach4,5, T Nicholas Domitrovic6,7, Jared R Rispens4,5, Andrea M Hujer6,7, Nadia K Qureshi8, Steven H Marshall6, David C Nguyen4,7,5, Susan D Rudin6, Xiaotian Zheng9,10, Sreenivas Konda11, Robert A Weinstein5,12, Robert A Bonomo6,7,13,14,15,16.
Abstract
INTRODUCTION: The pandemic of extended-spectrum beta-lactamase-(ESBL)-producing Enterobacteriaceae (Ent) is strongly linked to the dissemination of CTX-M-type-ESBL-Ent. We sought to define the epidemiology of infections in children due to an emerging resistance type, CTX-M-9-group-producing-Ent (CTX-M-9-grp-Ent).Entities:
Keywords: Children; Drug resistance; Enterobacteriaceae infections; Epidemiology; Gram-negative bacteria
Year: 2019 PMID: 30772921 PMCID: PMC6522575 DOI: 10.1007/s40121-019-0237-2
Source DB: PubMed Journal: Infect Dis Ther ISSN: 2193-6382
Characteristics of CTX M-9-grp extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and ESC-sensitive Enterobacteriaceae (ESC-S)
| CTX M-9-grp ESBL ( | ESC-S ( | |
|---|---|---|
| Species, | ||
| | 3 (7) | 23 (17) |
| | 40 (91) | 78 (59) |
| | 1 (2) | 21 (16) |
| Other Enterobacteriaceae | 0 (0) | 10 (7) |
| Source, | ||
| Urine | 31 (70) | 95 (72) |
| Respiratory | 7 (16) | 20 (15) |
| Blood | 4 (9) | 12 (9) |
| Othera | 2 (5) | 5 (4) |
ESC extended-spectrum cephalosporin
aOther includes wound, abscess, abdominal, and peritoneal sources
Anatomical sites of isolation and antibiotic susceptibility patterns of CTX-M-9-grp-producing Enterobacteriaceae
| Anatomical sitea | No. of isolatesb | % Susceptible (no. susceptible/no. available for testing)b | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTX | CAZ | FEP | P/T | CPM | GNT | TOB | AMK | FQ | TMP-SMX | TET | NIT | ||
| All | 44 | 0 | 0 | 0 | 100 (31/31) | 100 | 82 | 82 | 100 (40/40) | 52 (22/42) | 38 (16/42) | 22 (6/27) | 97 (30/31) |
| Urine | 31 | 0 | 0 | 0 | 100 (21/21) | 100 | 90 | 90 | 100 (28/28) | 52 (15/29) | 33 (10/30) | 24 (6/25) | 97 (30/31) |
| Respiratory | 7 | 0 | 0 | 0 | 100 (4/4) | 100 | 71 | 71 | 100 | 71 | 83 (5/6) | 0 (0/1) | ND |
| Blood | 4 | 0 | 0 | 0 | 100 | 100 | 50 | 50 | 100 (3/3) | 50 | 25 | 0 (0/1) | ND |
| Other | 2 | 0 | 0 | 0 | 100 | 100 | 50 | 50 | 100 | 0 | 0 | ND | ND |
CTX ceftriaxone, CAZ cefazolin, FEP cefepime, P/T piperacillin-tazobactam, CPM carbapenem (includes meropenem ertapenem or imipenem), GNT gentamicin, TOB tobramycin, AMK amikacin, FQ fluoroquinolones (includes ciprofloxacin and levofloxacin), TMP-SMX trimethoprim-sulfamethoxazole, TET tetracycline, NIT nitrofurantoin, ATN aztreonam, ND no data
aRespiratory includes bronchoalveolar lavage fluid, trachea, and sputum cultures. “Other” includes abscesses
bSusceptibility data not available for all antibiotics for all isolates
Bivariate analysis of demographics and factors associated with CTX-M-9-grp Enterobacteriaceae infections in children
| Characteristica | CTX-M-9-grp Ent infection | ESC-S Ent infectionb | |
|---|---|---|---|
| Patient | |||
| Age | 4.14 (0–20.8) | 4.48 (0–20.9) | 0.11 |
| Female | 29 (65.9) | 92 (69.7) | 0.64 |
| Race, White | 15 (34.1) | 38 (28.8) | 0.51 |
| Race, Black | 3 (6.8) | 29 (22.0) | 0.03 |
| Race, Hispanic | 15 (34.1) | 59 (44.7) | 0.22 |
| Race, non-White, non-Black, non-Hispanic | 11 (25) | 6 (4.6) | < 0.0001 |
| Location at diagnosis | < 0.0001 | ||
| Inpatient, non-ICU | 7 (15.9) | 42 (31.8) | 0.04 |
| Outpatient clinic | 16 (36.4) | 10 (7. 6) | < 0.001 |
| Emergency room | 9 (20.5) | 23 (17.4) | 0.65 |
| Pediatric ICU | 9 (20.5) | 39 (29.6) | 0.24 |
| Neonatal ICU | 3 (6.8) | 18 (13.6) | 0.22 |
| Recent CTXe | 9 (15.9) | 33 (25) | 0.21 |
| Recent FQf | 3 (6.8) | 4 (3.0) | 0.27 |
| Recent TMP/SMXg | 5 (11.4) | 18 (13.9) | 0.68 |
| Region of residencec | 0.01 | ||
| Recent health care | 0.01 | ||
| Inpatient care | 11 (25) | 34 (25.8) | 0.92 |
| Outpatient cared | 10 (22.7) | 59 (44.7) | 0.01 |
| No recent care | 23 (52.3) | 39 (29.6) | 0.006 |
| Foreign body present | 19 (43.2) | 75 (56.8) | 0.12 |
| Multiple foreign bodies present | 13 (29.6) | 49 (37.1) | 0.36 |
| Central venous line comorbidities | 8 (18.2) | 44 (33.3) | 0.03 |
| Cardiovascular | 7 (15.9) | 29 (22.0) | 0.39 |
| Endocrine | 2 (4.6) | 9 (7.0) | 0.73 |
| Gastrointestinal | 12 (27.3) | 32 (24.2) | 0.69 |
| Genitourinary | 14 (26.4) | 37 (28.0) | 0.82 |
| Hematology | 6 (13.6) | 20 (15.2) | 0.81 |
| Neurology | 14 (31.8) | 47 (35.6) | 0.65 |
| Respiratory | 8 (18.2) | 47 (35.6) | 0.03 |
| Renal | 13 (29.6) | 41 (31.1) | 0.85 |
| Multiple comorbidities | 18 (40.9) | 63 (47.0) | 0.49 |
aValues represent n (%) unless otherwise indicated
bESC-S Ent infections were children with infections due to Enterobacteriaceae sensitive to extended-spectrum cephalosporin antibiotics
cRegion of residence includes city region and neighboring suburbs
dOutpatient care includes care outside of routine child care visits and outpatient procedures
eAbbreviation CTX includes extended-spectrum cephalosporins (ceftriaxone, ceftazidime, cefotaxime, cefepime)
fFQ, fluoroquinolones (ciprofloxacin and levofloxacin)
gTMP-SMX, trimethoprim-sulfamethoxazole
Multivariable analysis of factors associated with CTX-M-9-grp Enterobacteriaceae infections in children
| Associated factors with CTX-M-9-grp Ent infectiona,c | OR | 95% CI | |
|---|---|---|---|
| Infection with | 7.4 | 2.4, 27.2 | 0.001 |
| Home residence in South region (South Chicago and South suburbs)b | 6.7 | 1.1, 37.9 | 0.03 |
| Race not White, Black or Hispanic | 7.4 | 2.4, 28.2 | 0.002 |
| Outpatient clinic location at time of infection diagnosis | 4.5 | 1.7, 12.3 | 0.003 |
| Home residence in Northwest region (NW Chicago and NW suburbs) | 0.19 | 0.04, 0.90 | 0.03 |
aEnt, Enterobacteriaceae
bReference region, West region
cControl group was children with Ent infections sensitive to extended-spectrum cephalosporins